Bli medlem
Bli medlem

Du är här

2016-05-04

Actelion Pharmaceuticals Ltd: Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved

Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of
Shareholders held in Basel, Switzerland -All Board proposals approved .
Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 04 May 2016 -
At today's Annual General Meeting (AGM) of Actelion Ltd (SIX: ATLN), held in
Basel, Switzerland, shareholders voted in favor of all proposals by the Board
of Directors with a significant majority.

The meeting was attended by 246 shareholders. A total of 61'781'591 shares, or
54.13% of the total outstanding shares, was represented.

Led by the Chairman of the Board, Jean-Pierre Garnier, the company presented a
review of the 2015 performance. The Chairman commented: "Over the last 15
months, Actelion has become a much stronger company. Firstly, the continued
success of Opsumit exceeded our expectations all over the world. Secondly, we
saw the timely FDA approval and successful US launch of Uptravi. Thirdly, we
made solid progress in advancing key assets of our growing clinical pipeline
of new drugs. This impressive scorecard was achieved while delivering a total
shareholder return of 22% in 2015. Actelion is now very well positioned for a
bright future. I would like to thank our management team and all our
employees for their efforts in building Actelion, and our shareholders for
their continued support."

The shareholders approved all of the Board's proposals, including the Annual
Report 2015 as well as the Statutory and the Consolidated Financial
Statements for 2015.

A proposal by the Board to distribute a dividend out of legal reserve
originating from capital contribution in the amount of CHF 1.50 per
registered share was passed by shareholders. The ex-dividend date will be 9
May 2016 and the payment will be made on 11 May 2016.

Shareholders endorsed the 2015 compensation report by way of consultative
vote.

Shareholders also approved the aggregate maximum compensation for the Board of
Directors (Non-Executive Directors) for the term until the AGM 2017 and the
aggregate compensation amount for the Actelion Executive Committee (AEC) for
the financial year 2017.
The shareholders granted discharge to all members of the Board of Directors
and of the Executive Management and re-elected all members of the Board which
stood for election for a term of office until the conclusion of the AGM 2017.

In addition, the shareholders elected Mr. Jean-Pierre Garnier as Chairperson
of the Board and Ms. Herna Verhagen, Mr. Jean-Pierre Garnier, and Mr. John J.
Greisch (Chair) to the Compensation Committee.

Following the AGM, the Board of Directors of Actelion comprises a total of 10
members: Jean-Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini,
Jean-Paul Clozel, John J. Greisch, Peter Gruss, Michael Jacobi, Jean Malo,
David Stout and Herna Verhagen.

BDO AG, represented by Mr. Marc Schaffner, was elected as Independent Proxy
for a term of office until the conclusion of the AGM 2017.

Ernst&Young was re-elected as the company's statutory auditors for the
business year 2016.

###

NOTES TO THE EDITOR

ABOUT ACTELION LTD.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH).
Our portfolio of PAH treatments covers the spectrum of disease, from WHO
Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous
medications. Although not available in all countries, Actelion has treatments
approved by health authorities for a number of specialist diseases including
Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in
patients suffering from systemic sclerosis, and mycosis fungoides in patients
with cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,500 dedicated professionals covering all
key markets around the world including the US, Japan, China, Russia and
Mexico, Actelion has its corporate headquarters in Allschwil / Basel,
Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All
trademarks are legally protected.
For further information please contact:

Andrew Weiss
Senior Vice President, Head of Investor Relations&Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
www.actelion.com

Press release PDF
http://hugin.info/131801/R/2009851/743851.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire

HUG#2009851

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.